Business Context and Reporting Period
Company: Novo Nordisk A/S
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: October 7, 2024
Subject: Update on Share Repurchase Programme
Novo Nordisk is a leading global healthcare company headquartered in Denmark, employing approximately 69,000 people across 80 countries. The filing reports on the execution of a share repurchase programme initiated on August 7, 2024, which is part of a broader DKK 20 billion programme authorized for a 12-month period beginning February 6, 2024.
Key Financial Metrics
This filing focuses on capital allocation activities rather than operational financial performance. Key metrics related to the share repurchase programme include:
- Total Repurchase Programme Cap: DKK 20 billion (12-month period starting Feb 6, 2024).
- Specific Sub-Programme (Aug 7 - Nov 4, 2024): Up to DKK 2.4 billion.
- Cumulative Repurchases (Since Feb 6, 2024): 12,896,648 B shares.
- Cumulative Transaction Value (Since Feb 6, 2024): DKK 11,339,024,603.
- Average Share Price (Since Feb 6, 2024): DKK 879.22 per B share.
- Treasury Shares Held: 14,225,279 B shares (0.3% of share capital).
Note: The filing text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Recent Activity
The filing details transactions executed between October 1 and October 4, 2024, following a previous announcement on September 30, 2024. Recent activity under the specific sub-programme includes:
- Oct 1: 42,000 shares at DKK 789.33 (Value: DKK 33,151,683).
- Oct 2: 44,500 shares at DKK 800.02 (Value: DKK 35,600,886).
- Oct 3: 54,964 shares at DKK 789.23 (Value: DKK 43,379,237).
- Oct 4: 42,000 shares at DKK 776.48 (Value: DKK 32,612,011).
As of October 4, 2024, the accumulated value under the specific August 7 programme reached DKK 1,611,318,553 for 1,829,522 shares.
Guidance, Outlook, and Risks
Outlook: Novo Nordisk expects to continue repurchasing B shares up to the total limit of DKK 20 billion during the 12-month period beginning February 6, 2024. The company aims to defeat serious chronic diseases through scientific breakthroughs and expanded access to medicines.
Risks and Contingencies: The filing does not explicitly list new risks or contingencies. It notes that the repurchase programme is conducted in accordance with the EU Market Abuse Regulation (MAR) and Safe Harbour Rules.
Investor Verification Checklist
- Verify the remaining capacity of the DKK 20 billion total repurchase programme (approx. DKK 8.66 billion remaining as of Oct 4).
- Confirm the current market price of Novo Nordisk B shares relative to the recent average purchase price of DKK 879.22.
- Review the full list of daily transactions on the company's official website (novonordisk.com) for updates post-October 4.
- Monitor the impact of treasury shares (currently 0.3% of capital) on earnings per share calculations in future earnings reports.